Fibroblast Growth Factor Receptors-1 and -3 Play Distinct Roles in the Regulation of Bladder Cancer Growth and Metastasis: Implications for Therapeutic Targeting

p63 expression correlates with sensitivity to the Eg5 inhibitor AZD4877 in bladder cancer cells

(2012) Lauren Marquis et al.   CANCER BIOLOGY & THERAPY

Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models

(2012) J. M. Gozgit et al.   MOLECULAR CANCER THERAPEUTICS

p63 Expression Defines a Lethal Subset of Muscle-Invasive Bladder Cancers

(2012) Woonyoung Choi et al.   PLoS One

FGFR1-Induced Epithelial to Mesenchymal Transition through MAPK/PLCγ/COX-2-Mediated Mechanisms

(2012) Darren C. Tomlinson et al.   PLoS One

New Strategies in Muscle-Invasive Bladder Cancer: On the Road to Personalized Medicine

(2011) J. B. Shah et al.   CLINICAL CANCER RESEARCH

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

(2011) Vito Guagnano et al.   JOURNAL OF MEDICINAL CHEMISTRY

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo

(2010) F R Lamont et al.   BRITISH JOURNAL OF CANCER

Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer

(2009) D. C. Tomlinson et al.   CANCER RESEARCH

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice

(2009) Jing Qing et al.   JOURNAL OF CLINICAL INVESTIGATION

1-tert-Butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a Selective Tyrosine Kinase Inhibitor of Fibroblast Growth Factor Receptor-3 (FGFR3), Inhibits Cell Proliferation of Bladder Cancer Carrying the FGFR3 Gene Mutation along with Up-Regulation of p27/Kip1 and G1/G0 Arrest

(2009) M. Miyake et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner

(2009) E di Martino et al.   ONCOGENE

Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells

(2008) P. C. Black et al.   CLINICAL CANCER RESEARCH

Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors

(2008) Margaret A Knowles   Future Oncology